5 Liters

Did you catch us at #ASH24 last weekend? We were thrilled to be part of the brilliant displays of technology and innovation moving the field of hematology forward. We are grateful to have been able to share our interim trial results for the revolutionary neural tourniquet with everyone who stopped by our booth and look forward to continuing to shape better patient outcomes in hematology. To connect with us about the neural tourniquet visit https://bit.ly/4gzFktx #Innovation

?? We are headed to the West Coast! The 66th Annual American Society of Hematology Meeting is this weekend in sunny San Diego! Join us this Saturday, Dec 7 – Monday, Dec 9 at booth 2511 to learn about the revolutionary Neural Tourniquet and see our interim trial results. We hope to see you there! #Hemostasis #SparrowAscent #Innovation

Spark Biomedical Inc will be presenting results at ASH: American Society of Hematology meeting in December re how their device can help manage severe bleeding. Be sure to stop by their booth at ASH.

??Five Liters is going to sunny San Diego! Five Liters, a Spark Biomedical Inc company, will be exhibiting at the annual American Society of Hematology meeting next month! We look forward to sharing the pioneering results of our Healthy Human Hemostasis Study, which explored the activation of the Neural Tourniquet via transcutaneous auricular neurostimulation. ?? Join us at Booth 2511 to discover how this innovative technology is paving a better way forward for patient care in hematology. #ASH24 #Hemostasis #MedTech

It was super exciting to watch Jared Huston present the results of our first-in-human study at this year's Society for Neuroscience annual meeting. But honestly, it was just as exciting to see our work get picked up in the journal Nature Magazine! Shout out to Max Kozlov for writing this great piece!!

Researchers are exploring a new method to reduce uncontrolled bleeding through electrical stimulation near the ear, a technique they call a "neural tourniquet." This approach enhances platelet activation by stimulating the spleen via the vagus nerve, which stores a large percentage of the body’s platelets. Early tests on pigs and mice showed significant reductions in blood loss and faster clotting. Preliminary human trials have indicated modest increases in clot stability, though the time required for platelet activation (about two hours) may limit its immediate applicability in emergency settings. A clinical trial is underway for testing the device for reducing menstrual bleeding through a clinical trial targeting women with type 1 von Willebrand disease, a condition associated with excessive menstrual bleeding. Link: https://lnkd.in/eQjz4fki Link to clinical trial: https://lnkd.in/enauDZds Spark Biomedical Inc Chris Czura, PhD Navid Khodaparast

Proud to be featured in Nature for our Neural Tourniquet! The article highlights our collaboration with The Feinstein Institutes for our recent first in human hemostasis trial. Read the full article to learn about our neural tourniquet: https://lnkd.in/gJc6MV-q #MedTech #HealthInnovation #Neurostimulation

What an inspiring few days at the Foundation for Women & Girls With Blood Disorders Conference! Thanks to everyone who stopped by to learn about Spark Biomedical Inc's role in advancing treatment for blood disorders. Your interest and discussions enrich our commitment to enhancing healthcare through innovative neurostimulation technology. ?? Didn't get a chance to stop by our booth? Visit https://bit.ly/4d89IJm to learn more about wearable neurostimulation and the difference it can make for your patients. #FWGBD2024 #HealthInnovation #PatientBloodManagement #FemTech

Join Spark Biomedical at SABM in Phoenix next month! Come see Chris Czura, PhD, at Table 19 from Sept 11-14 to explore the capabilities of the Neural Tourniquet — Spark Biomedical's current clinical trial work leveraging wearable neurostimulation to accelerate the clotting process. Don’t miss the chance to discuss this technology directly with our experts and discover the unique potential of wearable neurostimulation. #SABM2024 #PatientBloodManagement #HealthInnovation #SparkBiomedical

At Spark Biomedical, we are actively developing solutions for individuals with von Willebrand Disease and heavy menstrual bleeding through our subsidiary, 5 Liters. Our ongoing clinical trials at 5 Liters are dedicated to establishing the efficacy of neurostimulation in managing bleeding disorders, aiming to improve the quality of life for the 3 million+ women affected by VWD and heavy menstrual bleeding. Discover more about our groundbreaking work at www.fiveliters.com.